This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Review paper

ARNI in cardiovascular disease: current evidence and future perspectives

Volume: 16, Issue: 5, Pages: 505 - 515
Published: Apr 22, 2020
Abstract
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the mainstay of therapy for cardiovascular disease and heart failure (HF). The angiotensin receptor II blocker – neprilysin inhibitor (ARNI), sacubitril-valsartan has an established role in treatment of patients with HF with reduced ejection fraction (HFrEF) based on the results of PARADIGM-HF trial. This trial has provided a strong evidence base for treatment of...
Paper Details
Title
ARNI in cardiovascular disease: current evidence and future perspectives
Published Date
Apr 22, 2020
Volume
16
Issue
5
Pages
505 - 515
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.